Assure Tech (Hangzhou) Co., Ltd.

Assure Tech (Hangzhou) Co., Ltd.

688075.SS
Assure Tech (Hangzhou) Co., Ltd.CN flagShanghai Stock Exchange
30.15
CNY
-0.77
- -
3.83BMarket Cap
Assure Tech (Hangzhou) Co., Ltd.
688075.SS
(Shanghai Stock Exchange)

Recent

price

30.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.28
3.13
2.32
12.59
16.22
48.5
3.95
4.25
3.58
4.14
Revenue per Share
-0.12
0.64
0.6
6.81
7.54
23.95
1.11
1.51
0.55
1.08
Basic EPS, GAAP
0.2
-0.12
0.11
5.9
4.86
24.52
-7.53
-0.25
-0.83
-0.86
Free Cash Flow per Basic Share
0.01
0.01
- -
- -
- -
1.87
3.57
0.8
0.81
0.42
Dividend per Share
0.4
1.04
0.93
7.49
14.89
33.68
31.39
32.04
32.06
32.03
Book Value per Share
1.3
1.96
1.79
8.47
26.37
42.3
39.61
40.47
40.54
40.56
Tangible Book Value per Share
49
52
90
95
98
127
128
127
126
126
Basic Weighted Avg Shares
111
164
210
1,200
1,589
6,166
503
541
451
522
Sales/Revenue/Turnover
1.08
25.71
30.26
67.28
56.74
59.96
5.52
1.53
-3.39
-4.7
Operating Margin (%)
2
3
4
4
12
46
64
53
48
- -
Depreciation Expense
-6
33
54
649
739
3,045
142
192
69
136
Net Income, GAAP
- -
18.65
12.6
14.77
14.58
13.51
1.98
8.74
7.56
8.24
Effective Tax Rate (%)
-5.28
20.38
25.96
54.09
46.47
49.38
28.12
35.56
15.38
26.09
Profit Margin (%)
21
59
118
732
2,322
4,848
4,264
4,295
4,155
4,230
Working Capital
- -
- -
- -
- -
2
34
8
4
2
3
LT Debt
64
103
162
812
2,606
5,419
5,106
5,200
5,161
5,155
Total Equity
- -
37.96
41.77
133.61
43.1
76.95
0.51
0.15
-0.27
-0.44
Return on Invested Capital (%)
- -
75.37
76.69
162.79
67.83
105.27
3.44
4.77
1.72
3.39
Return on Capital (%)
- -
90.58
78.87
162.78
67.97
106.07
3.42
4.76
1.71
3.36
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
4
- -
3
LT Borrowings
- -
- -
- -
LT Finance Leases
4
6
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
127
127
127
Market Capitalization
4,707
4,999
4,836

Working Capital

FRC

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
4,770
4,848
4,772
Cash, Cash Equivalents & STI
2,004
1,849
1,599
Accounts Receivable, Net
204
284
191
Inventories
147
144
136
Total Current Liabilities
475
498
543
Payables & Accruals
- -
- -
- -
ST Debt
4
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
64.86%
-0.75%
Free Cash Flow
- -
107.91%
227.92%
Net Income, GAAP
- -
40.53%
-63.9%
Sales/Revenue/Turnover
- -
43.9%
-16.54%
Total Cash Common Dividend
- -
- -
-0.03%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
129
119
155
137
541
2025
115
114
126
- -
451
2026
71
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
- -
- -
- -
1.51
2025
0.27
- -
- -
- -
0.55
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.8
2025
- -
- -
- -
- -
0.81
2026
- -
- -
- -
- -
- -
Business
Assure Tech (Hangzhou) Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic (IVD) reagents, point-of-care testing (POCT) reagents, and related biological materials. The company’s core product portfolio includes immunochromatographic test reagents and analyzers, dry biochemical detection reagents, chemiluminescence test reagents and analyzers, nucleic acid test reagents and analyzers, and veterinary diagnostic products. Its diagnostic test offerings cover a wide range of categories such as drug of abuse tests, infectious disease tests, fertility tests, tumor marker tests, cardiac marker tests, biochemical tests, allergy tests, and chronic disease series. Assure Tech also manufactures clinical analytical instruments including fluorescence immunoassay analyzers and multi-monitoring systems for various biomarkers. The company operates with a global footprint, marketing its products both domestically in China and internationally. Founded in 2008 and headquartered in Hangzhou, China, Assure Tech focuses on biotechnology and healthcare sectors with specialized expertise in POCT and IVD technologies. In recent developments within the last two years, Assure Tech has strategically launched new fluorescent diagnostic products that combine advanced fluorescence immunoassay technology with rapid testing capabilities, attracting industry attention. The company has also made strides in expanding its product lines to include more quantitative chemiluminescence immunoassay reagents and bioactive materials. Assure Tech maintains robust R&D efforts to support innovation across its test kits and analyzers, positioning itself strongly in emerging digital and automated diagnostic solutions. The company is publicly listed on the Shanghai Stock Exchange STAR Market under ticker 688075.SS. The latest operational focus includes broadening its infectious disease test portfolio and chronic disease-related diagnostics, complemented by continuous enhancement of its analyzer platforms for usability and accuracy improvements. Assure Tech’s customer base spans hospitals, laboratories, veterinary clinics, emergency responders, and law enforcement agencies targeting clinical, point-of-care, and field testing environments. The company’s sustained commitment to quality and innovation is bolstered by certifications including US FDA 510(k) clearance for multiple products and recognition as a high-tech biotechnology enterprise in China. Assure Tech’s comprehensive product suite and recent innovations reflect its strategic intent to lead in the immunoassay and rapid diagnostic reagent markets, leveraging fluorescence and molecular diagnostic technologies. Its international sales growth alongside domestic market penetration underscores a balanced geographic focus. The company’s operational headquarters is located at Building 4, No. 1418-50 Moganshan Road, Gongshu District, Hangzhou, Zhejiang Province, China. In summary, Assure Tech (Hangzhou) Co., Ltd. operates as an advanced biotechnology company specializing in the manufacture and global distribution of diagnostic reagents and analytical instruments, emphasizing POCT solutions, fluorescent immunoassays, and molecular diagnostics, with recent product launches marking significant technological upgrades and market expansion.